Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Lorusso, D; Hilpert, F; González Martin, A; Rau, J; Ottevanger, P; Greimel, E; Lück, Hj; Selle, F; Colombo, N; Kroep, Jr; Mirza, Mr; Berger, R; Pardo, B; Grischke, Em; Berton-Rigaud, D; Martinez-Garcia, J; Vergote, I; Redondo, A; Cardona, A; Bastière-Truchot, L; du Bois, A; Kurzeder, C; PENELOPE trial, Investigators.